立方制药：子公司洛索洛芬钠口服溶液获得药品注册证书

Core Viewpoint - The announcement by Cubic Pharmaceuticals regarding the approval of Loxoprofen Sodium Oral Solution by the National Medical Products Administration enhances the company's product pipeline and market competitiveness, as it becomes the eighth domestic company to hold this drug registration certificate [1] Group 1 - Cubic Pharmaceuticals' wholly-owned subsidiary, Chengzhi Biological, received the drug registration certificate for Loxoprofen Sodium Oral Solution, a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic effects [1] - As of the announcement date, there are no approved imported products for this drug in the domestic market, indicating a unique market position for Chengzhi Biological [1] - The acquisition of this certificate will further enrich the product pipeline of Cubic Pharmaceuticals, potentially enhancing its competitive edge in the market [1] Group 2 - The production and sales of the drug are still subject to policy and market factors, which introduces a level of uncertainty [1]